We'd absolutely love to see a drug identification number application put forward by a drug company, but one of the issues surrounding cannabis and what makes it unique is that it's a plant. It's not a patentable molecule, and that's typically what the therapeutic drug directorate regulates.
When talking about cannabis, there's a wide range of indications. Really, it does come back to the research. We need to focus on research specific to medical cannabis. The government has an obligation in this role, we believe, because of the limited patentability of cannabis, to really incentivize research and ensure that we have the research needed to get to that DIN. In the interim, we believe cannabis should be assigned a DIN or something equivalent to start facilitating reimbursement, as it's such a vital issue for patients across the country.